Theratechnologies develops therapies for unmet medical needs in commercially attractive specialty markets.

Theratechnologies

Theratechnologies (TSX:TH) is a Canadian biopharmaceutical company that discovers novel therapeutic products for development and commercialization. These products target unmet medical needs in commercially attractive specialty markets.

In the clinic

Tesamorelin Phase 3 Results

Find out more on the study

 

 

Products

Our lead product: tesamorelin

Antiretrovirals have increased the life expectancy of HIV patients. Despite the benefits of these therapies, they are associated with side-effects such as lipodystrophy. We are currently studying the effects of tesamorelin (TH9507) on excessive visceral fat, an important characteristic of HIV-associated lipodystrophy. More...

Investors

See our investor kit:

2008 Annual Report

Quarterly Report

First scientific symposium, sponsored by Theratechnologies, at the 11th European AIDS Conference.

Access the symposium's webcast


 

News

  • June 19, 2009 - Theratechnologies awarded Le Prix Santé by the Fondation Armand-Frappier More...
  • June 12, 2009 - Theratechnologies presents results from a pharmacokinetic/phamacodynamic evaluation of tesamorelin at the Endocrine Society’s Annual Meeting More...
  • June 1, 2009 - Theratechnologies files a New Drug Application for tesamorelin with the US Food and Drug Administration More...

Events

  • From April 28 to 30, 2009 - BioFinance 2009 More...